Emmecell announced the appointment of Ramin Valian as Chief Executive Officer. Mr. Valian brings more than 20 years of global commercial and strategic leadership in eye care, with expertise across corneal disease, surgical and interventional glaucoma, retina, and consumer eye care.

Over the course of his career, Mr. Valian has led the launch of six ophthalmic products spanning both therapeutics and medical technologies. He joins Emmecell following a tenure at Allergan and AbbVie, where he played key roles in global strategy, clinical development, and commercialization of several high-impact ophthalmic products. His decision to join Emmecell reflects confidence in the company’s scientific foundation, proprietary platform, and potential to deliver meaningful clinical benefit to patients.

“I believe Emmecell’s magnetic cell delivery technology has the potential to fundamentally redefine ophthalmic treatment—from corneal disease to geographic atrophy,” Mr. Valian said. “The ability to precisely and noninvasively position therapeutic cells opens new possibilities for regenerative medicine. I’m honored to lead Emmecell as it advances toward pivotal clinical development and commercialization.”

Emmecell’s magnetic cell delivery (MCD) platform is designed to enable targeted placement of therapeutic cells through a minimally invasive procedure. The company’s lead program is being developed as a potential non-surgical alternative to corneal transplant, aiming to overcome limitations related to donor tissue availability and the burden of invasive surgery. In parallel, Emmecell is advancing a novel cell therapy approach for geographic atrophy.

“We are pleased to welcome Ramin to Emmecell. His proven leadership, deep ophthalmology expertise, and commitment to patient-centered innovation make him the right CEO to guide Emmecell as we advance programs in both corneal and retinal disease," said Jeffrey L. Goldberg, MD, PhD, Co-Founder and Chairman of the Board.